Collegium Pharmaceutical (COLL) Short term Debt (2014 - 2026)

Collegium Pharmaceutical has reported Short term Debt for 13 years, with the latest figure at $55.0 million in Q2 2026.

• On a quarterly basis, Short term Debt fell 14.84% year-over-year to $55.0 million in Q2 2026; TTM through Jun 2026 was $55.0 million, a 14.84% decrease from a year earlier, with the FY2025 full-year figure at $29.0 million, down 55.1% from the prior year.
• Short term Debt was $55.0 million for Q2 2026 at Collegium Pharmaceutical, up from $32.6 million in the prior quarter.
• The five-year high for Short term Debt was $183.3 million in Q1 2023, with the low at $29.0 million in Q4 2025.
• Average Short term Debt over 5 years is $114.7 million, with a median of $110.4 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2024: Short term Debt soared 236.07% in 2022, then tumbled 64.77% in 2024.
• Over 5 years, Short term Debt stood at $162.5 million in 2022, then climbed by 12.82% to $183.3 million in 2023, then sank by 64.77% to $64.6 million in 2024, then sank by 55.1% to $29.0 million in 2025, then soared by 89.66% to $55.0 million in 2026.
• The last three Short term Debt figures came in at $55.0 million (Q2 2026), $32.6 million (Q1 2026), and $29.0 million (Q4 2025), per Business Quant data.